| P2093 | author name string | Michael A. Davies | |
| P2860 | cites work | Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 |
| | Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma | Q24561567 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | The PI3K pathway as drug target in human cancer | Q24632283 |
| | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| | First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors | Q27851678 |
| | The phosphoinositide 3-kinase pathway | Q27860738 |
| | PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 |
| | Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 |
| | Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set | Q28389579 |
| | Role for Akt3/protein kinase Bgamma in attainment of normal brain size | Q28509294 |
| | mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 |
| | Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 |
| | PI3K pathway alterations in cancer: variations on a theme | Q29615530 |
| | Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) | Q29615537 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | Deregulated Akt3 activity promotes development of malignant melanoma | Q34355872 |
| | AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 |
| | AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer | Q34990362 |
| | PTEN signaling pathways in melanoma | Q35146572 |
| | A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities | Q35701021 |
| | Epigenetic PTEN silencing in malignant melanomas without PTEN mutation | Q35745799 |
| | Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition | Q36320600 |
| | Point mutations of protein kinases and individualised cancer therapy | Q36632245 |
| | Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 |
| | An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 |
| | Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 |
| | Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 |
| | PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival | Q39987929 |
| | Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. | Q41859138 |
| | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 |
| | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 |
| | Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. | Q46708758 |
| | Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab | Q81151636 |
| P433 | issue | 35 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4715-4717 | |
| P577 | publication date | 2011-10-24 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Regulation, role, and targeting of Akt in cancer | |
| | Regulation, Role, and Targeting of Akt in Cancer | |
| P478 | volume | 29 | |